Soligenix, Inc. Files 8-K Report

TL;DR

SOLIGENIX filed an 8-K, mostly financial docs. No major news.

AI Summary

On August 16, 2024, Soligenix, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating a routine update rather than a major event. No specific financial figures or significant business developments were detailed in the provided excerpt.

Why It Matters

This filing serves as a notification to investors about the company's financial reporting and exhibits, which is a standard regulatory requirement.

Risk Assessment

Risk Level: low — The filing appears to be a routine submission of financial statements and exhibits, with no immediate indication of significant positive or negative developments.

Key Players & Entities

• SOLIGENIX, INC. (company) — Filer
• August 16, 2024 (date) — Date of Report
• 001-14778 (other) — Commission File Number
• 29 Emmons Drive, Suite B-10 Princeton, NJ 08540 (address) — Principal Executive Offices

FAQ

Key Financial Figures

• $0.001 — , shares of its common stock, par value $0.001 per share, having an aggregate offering
• $5.8 m — ng an aggregate offering price of up to $5.8 million, through AGP, as sales agent. U

Filing Documents

• sngx-20240816x8k.htm (8-K) — 42KB
• sngx-20240816xex5d1.htm (EX-5.1) — 29KB
• sngx-20240816xex10d1.htm (EX-10.1) — 411KB
• sngx-20240816xex5d1001.jpg (GRAPHIC) — 4KB
• sngx-20240816xex5d1002.jpg (GRAPHIC) — 3KB
• 0001558370-24-012345.txt ( ) — 688KB
• sngx-20240816.xsd (EX-101.SCH) — 4KB
• sngx-20240816_def.xml (EX-101.DEF) — 3KB
• sngx-20240816_lab.xml (EX-101.LAB) — 17KB
• sngx-20240816_pre.xml (EX-101.PRE) — 10KB
• sngx-20240816x8k_htm.xml (XML) — 5KB

01. Other Events

Item 8.01. Other Events. On August 16, 2024, Soligenix, Inc. (the "Company") and A.G.P./Alliance Global Partners ("AGP") entered into an At Market Issuance Sales Agreement (as amended, the "Sales Agreement"), pursuant to which the Company may sell from time to time, at its option, shares of its common stock, par value $0.001 per share, having an aggregate offering price of up to $5.8 million, through AGP, as sales agent. Under the Sales Agreement, the Company will set the parameters for the sale of shares, including the number of shares to be issued, the time period during which sales are requested to be made, limitation on the number of shares that may be sold in any one trading day and any minimum price below which sales may not be made. Subject to the terms and conditions of the Sales Agreement, AGP may sell the shares by any method permitted by law deemed to be an "at-the-market offering" as defined in Rule 415 promulgated under the Securities Act of 1933, as amended (the "Securities Act"), including sales made directly on The Nasdaq Capital Market, the trading market for the Company's common stock, or any other existing trading market in the United States for the common stock, sales made to or through a market maker other than on an exchange, at prices related to the prevailing market prices or at negotiated prices. The Company cannot provide any assurances that it will issue any shares pursuant to the Sales Agreement. The Sales Agreement may be terminated by the Company upon notice to AGP or by AGP upon notice to the Company, or at any time under certain circumstances, including but not limited to the occurrence of a material adverse change in the Company. The offering of shares of common stock pursuant to the Sales Agreement will terminate upon the earliest of (a) December 15, 2026, (b) the sale of all of the shares of common stock subject to the Sales Agreement, (c) the termination of the Sales Agreement by AGP or the Company, as permitted therein, and (

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 5.1 Opinion of Duane Morris LLP 10.1 At Market Issuance Sales Agreement dated August 16, 2024 between Soligenix, Inc. and A.G.P./Alliance Global Partners 23.1 Consent of Duane Morris LLP (included in Exhibit 5.1) 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 3 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Soligenix, Inc. August 16, 2024 By: /s/ Christopher J. Schaber Christopher J. Schaber, Ph.D. President and Chief Executive Officer (Principal Executive Officer) 4

View Full Filing

View this 8-K filing on SEC EDGAR